Litigation Details for Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)
✉ Email this page to a colleague
Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-09-13 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,188,632; 8,691,860; 9,115,091; 9,364,489; 9,675,587; 9,789,125 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan USA, Inc. v. Aurobindo Pharma Ltd.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-01-10 | 140 | Opinion - Memorandum Opinion | the ʼ489 patent”), 9,789,125 (“the ʼ125 patent”), 9,675,587 (“the ʼ587 patent”), and 10,188,632 (“the ʼ632…terms in U.S. Patent Nos. 8,691,860, 9,115,091, 9,364,489, 9,789,125, 9,675,587, and 10,188,632.. Signed by…Crystalline Form Patents are the ʼ860 patent, the ʼ091 patent, the ʼ489 patent, and the ʼ125 patent. The Abuse-Deterrent… terms in U.S. Patent Nos. 8,691,860 (“the ’860 patent”), 9,115,091 (“the ʼ091 patent”), 9,364,489 (“…Abuse-Deterrent Patents are the ʼ587 patent and the ʼ632 patent. The parties agreed on the constructions | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
